This study designed a bismuth nanoparticle coated with tea polyphenols and fucoidan that delivers bismuth ions to Helicobacter pylori, where bismuth competes with iron and starves the bacterium. In infected mice it lowered stomach colonization and, by 16S rRNA sequencing, left the gut bacterial community close to that of uninfected mice, whereas a standard quadruple therapy containing bismuth potassium citrate and antibiotics disrupted it. The authors note that tissue accumulation and long-term safety still need study.
Key numbers
- Mouse dosing for five days by gavage: nanodrug at 10 mg/mL, or quadruple therapy of amoxicillin 303, levofloxacin 61, esomeprazole 6 and bismuth potassium citrate 182 mg/kg; eight mice per group (p. 19).
- Gut microbiota composition in the nanodrug group was close to that of normal mice, while the quadruple therapy group was clearly altered; quadruple therapy lowered fecal caproic, acetic and butyric acids (p. 13, Figure 9).
- Body weights stayed stable and no obvious lesions were seen in major organs after nanodrug treatment (p. 13).
- Bismuth ion release from the nanodrug was measured by ICP-MS in buffer and simulated gastric fluid (p. 20; data in supplement).
Methods (brief)
Nanoparticles were prepared from bismuth, tea polyphenols and fucoidan and tested against H. pylori strains in culture, including resistant clinical isolates. Infected C57BL/6J mice were treated for five days and examined for colonization, histology, fecal microbiota by 16S rRNA sequencing and short-chain fatty acids by targeted metabolomics. Intracellular iron and bismuth were measured by ICP-MS.
Evidence fitness
The study supports statements that bismuth can act as an iron mimic against H. pylori and that, in mice, a polyphenol-coated bismuth nanodrug altered gut bacteria less than an antibiotic-containing quadruple therapy. It does not isolate the effect of bismuth on the microbiota, because the comparison regimen also contained two antibiotics, and it does not support statements on dietary bismuth or human safety.
Limitations
Short five-day mouse experiment with small groups; microbiota differences reflect whole regimens, not bismuth alone. The authors state that pharmacokinetics, long-term biosafety and toxicology remain to be evaluated (p. 15). Detailed release and tissue data are in supplementary files that were not reviewed.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.